Innovative APIs
Novel Mode of Action
A century after penicillin, we’re entering a new era of antibiotics. Our patented pyrimidine-based APIs reinvent how we target the bacterial cell wall — hitting multiple points to shut down even the toughest drug-resistant infections. This pleiotropic mechanism disrupts antimicrobial resistance, stopping infections at the source.
- Multiple cell wall targets
- Pleiotropic effects break resistance mechanisms
- Effective in preventing and treating difficult infections caused by both Gram-positive and Gram-negative bacteria
Engineered to Outpace Resistance
Antibiotic resistance is rising — turning manageable infections into serious threats. Our APIs work with antibiotics to enhance their effect, lower required doses, and have shown strong results in major clinical trials — with no known resistance.
- Boosts antibiotic effectiveness
- Enables lower antibiotic dosages
- Clinically proven results
- No known resistance
Fluometacyl®: Dual-action API
Our patented API is built from a metabolite of an FDA-approved drug with full toxicology data. It delivers strong efficacy without added regulatory burden. When Fluometacyl® is paired with CMD-COAT™, it produces the first dual-action coating with both antimicrobial and antithrombotic properties.
- First-of-its-kind antimicrobial and antithrombotic coating
- Proven synergy from known, safe components
- No added regulatory or chemical complexity
Future Applications
Medical device coatings are just the beginning. Our APIs are built for two key paths:
- Coating applications using FDA-derived API combinations — safe, effective, and ready for clinical use.
- Pharmaceutical development of novel antimicrobial APIs — targeting resistant infections through topical, oral, nebulized, and IV delivery.
Manufacturing-Ready. Scalable by Design.
CMD-COAT™ was engineered not just for performance, but for seamless integration into medical device manufacturing
— with no added time, complexity, or environmental burden. CM4CURE
Water-Based, Solvent-Free Process
Water-based mixing and application
Room temperature processing
No UV curing, thermal treatment, or post-processing required
More ecofriendly than solvent-based systems
Fast, Simple, and Familiar
No change to production timelines
Pre-mixed materials — no on-site chemistry required
Easy adoption with existing workflows
Wide Material Compatibility
Ultra-thin yet durable layer
No material deterioration
Maintains flexibility and function
Full Coverage - Inside and Out
Solving Critical Risks in IV Catheters
Bloodstream infections from IV catheters can cost up to $46,000 per episode and carry a 15% mortality rate. Thrombosis affects up to 18% of patients, compounding risk and driving up costs. Existing coatings offer limited protection. CMD-COAT™ goes further.
Paired with our patented Fluometacyl® API, it delivers first-of-its-kind dual protection against both infection and thrombosis — all in a single, ultra-thin, hydrophilic layer.
CMD-COAT™ is designed to scale across insertable and implantable devices — and beyond.
0.1% - 9%
$46k per episode
15% Mortality
Bloodstream Infection
5% - 18%
$5k per episode
Increased Infection Risk
Thrombosis
Expanding What’s Possible
IV catheters are just the beginning. Our nanogel platform, CMD-COAT™, is designed to enhance safety and performance across a wide range of medical devices — from high-risk insertables to long-term implants.
Potential applications span:
- Urinary Catheters
- Port-a-Cath IV Access
- Heart Valve Implants
- Prosthesis
- Hemodialysis Catheters
- Breast Implants
- Stents
- Pacemakers
With programmable API delivery, exceptional passive protection, and potential for new API formats, it’s a new frontier for coating technology.
Meet the Team
Behind this revolutionary platform is a team of leading clinicians, scientists, engineers, and business strategists working to change the future of medical device coatings and patient care.